Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
The consensus price target hints at a 38.9% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
| Health Care Equipment & Supplies Industry | Healthcare Sector | Keith W. Pfeil CEO | XETRA Exchange | US3795772082 ISIN |
| US Country | 5,300 Employees | - Last Dividend | - Last Split | 3 Aug 2012 IPO Date |
Globus Medical, Inc. is a prominent medical device company focused on innovating healthcare solutions for patients dealing with musculoskeletal disorders, serving both the United States and international markets. Since its inception in 2003, Globus Medical has been at the forefront of developing a wide range of medical devices aimed at improving the quality of life for patients suffering from a variety of conditions, including degenerative and congenital disorders, deformities, tumors, and trauma injuries. With its headquarters located in Audubon, Pennsylvania, Globus Medical has established a strong global presence, distributing its products through a mix of direct sales, distributor representatives, and independent sales agents.
Globus Medical, Inc. offers an extensive portfolio of products and solutions across multiple domains within the musculoskeletal treatment spectrum:
Apart from its direct contribution to improving patient outcomes with its products, Globus Medical also engages in the distribution of human cell, tissue, and cellular and tissue-based products, leveraging its extensive network to facilitate availability across its served markets.